Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC
Public ClinicalTrials.gov record NCT00544648. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I/II Study of Nab-Paclitaxel and Carboplatin With Concurrent Radiation Therapy for Unresectable Stage III Non-Small-Cell Lung Cancer (NSCLC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation) may make tumor cells more sensitive to radiation therapy. Giving nab-paclitaxel together with radiation therapy and carboplatin may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of giving nab-paclitaxel together with carboplatin and radiation therapy and to see how well it works in treating patients with stage III non-small-cell lung cancer that cannot be removed by surgery.
Study identification
- NCT ID
- NCT00544648
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 13 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2007 (Type not available)
- Primary completion
- Apr 2014 (Actual)
- Completion
- Apr 2014 (Actual)
- Last update posted
- Jun 9, 2014
2007 – 2014
United States locations
- U.S. sites
- 6
- U.S. states
- 3
- U.S. cities
- 4
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Purchase Cancer Group - Paducah | Paducah | Kentucky | 42002 | — |
| Oregon Health Sciences University | Portland | Oregon | 97201 | — |
| Erlanger Cancer Center at Erlanger Hospital - Baroness | Chattanooga | Tennessee | 37403 | — |
| Vanderbilt-Ingram Cancer Center - Cool Springs | Nashville | Tennessee | 37064 | — |
| Vanderbilt-Ingram Cancer Center at Franklin | Nashville | Tennessee | 37064 | — |
| Vanderbilt-Ingram Cancer Center | Nashville | Tennessee | 37232-6838 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Lung Cancer trials
Other public records listing Lung Cancer. Sorted by last update posted; newest first. Not a recommendation.
- NCT06360822: Increasing Equity in Lung Cancer Screening Recruiting
- NCT00001823: Evaluation for NCI Surgery Branch Clinical Research Protocols Recruiting
- NCT07795411: Prospective Multiomic Analysis in Small-Cell Lung Cancer Not yet recruiting
- NCT07792824: Witness Project Lung Not yet recruiting
- NCT06636721: Lung Cancer and Aging: Improving Well-being for Older Adults With Lung Cancer Not yet recruiting
- NCT06577987: Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00544648, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 9, 2014 · Synced Sep 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00544648 live on ClinicalTrials.gov.